139 related articles for article (PubMed ID: 26975539)
1. Plasma osteoprotegerin levels are inversely associated with nonalcoholic fatty liver disease in patients with type 2 diabetes: A case-control study in China.
Niu Y; Zhang W; Yang Z; Li X; Fang W; Zhang H; Wang S; Zhou H; Fan J; Qin L; Su Q
Metabolism; 2016 Apr; 65(4):475-81. PubMed ID: 26975539
[TBL] [Abstract][Full Text] [Related]
2. Circulating mRNA and plasma levels of osteoprotegerin and receptor activator of NF-κB ligand in nonalcoholic fatty liver disease.
Nikseresht M; Azarmehr N; Arya A; Alipoor B; Fadaei R; Khalvati B; Abidi H; Doustimotlagh AH
Biotechnol Appl Biochem; 2021 Dec; 68(6):1243-1249. PubMed ID: 33010062
[TBL] [Abstract][Full Text] [Related]
3. The relation between carotid intima media thickness and serum osteoprotegerin levels in nonalcoholic fatty liver disease.
Ayaz T; Kirbas A; Durakoglugil T; Durakoglugil ME; Sahin SB; Sahin OZ; Kirvar A; Tasci F
Metab Syndr Relat Disord; 2014 Jun; 12(5):283-9. PubMed ID: 24689950
[TBL] [Abstract][Full Text] [Related]
4. Role of osteoprotegerin/receptor activator of nuclear factor kappa B/receptor activator of nuclear factor kappa B ligand axis in nonalcoholic fatty liver disease.
Pacifico L; Andreoli GM; D'Avanzo M; De Mitri D; Pierimarchi P
World J Gastroenterol; 2018 May; 24(19):2073-2082. PubMed ID: 29785076
[TBL] [Abstract][Full Text] [Related]
5. Prevalence of nonalcoholic fatty liver disease and liver cirrhosis in Chinese adults with type 2 diabetes mellitus.
Han X; Zhang X; Liu Z; Fan H; Guo C; Wang H; Gu Y; Zhang T
J Diabetes; 2024 May; 16(5):e13564. PubMed ID: 38664879
[TBL] [Abstract][Full Text] [Related]
6. Effect of metformin treatment on circulating osteoprotegerin in patients with nonalcoholic fatty liver disease.
Sofer E; Shargorodsky M
Hepatol Int; 2016 Jan; 10(1):169-74. PubMed ID: 26198758
[TBL] [Abstract][Full Text] [Related]
7. Similar to adiponectin, serum levels of osteoprotegerin are associated with obesity in healthy subjects.
Ashley DT; O'Sullivan EP; Davenport C; Devlin N; Crowley RK; McCaffrey N; Moyna NM; Smith D; O'Gorman DJ
Metabolism; 2011 Jul; 60(7):994-1000. PubMed ID: 21087777
[TBL] [Abstract][Full Text] [Related]
8. [Value of serum osteoprotegerin in noninvasive diagnosis of nonalcoholic steatohepatitis].
Yang M; Liu Y; Zhou G; Guo X; Zou S; Liu S; Jiang L; Liu Y; Zhu L; Guo C; Zhao J
Zhonghua Gan Zang Bing Za Zhi; 2016 Feb; 24(2):96-101. PubMed ID: 26983475
[TBL] [Abstract][Full Text] [Related]
9. Serum levels of osteoprotegerin in the spectrum of nonalcoholic fatty liver disease.
Yilmaz Y; Yonal O; Kurt R; Oral AY; Eren F; Ozdogan O; Ari F; Celikel CA; Korkmaz S; Ulukaya E; Imeryuz N; Kalayci C; Avsar E
Scand J Clin Lab Invest; 2010 Dec; 70(8):541-6. PubMed ID: 20942739
[TBL] [Abstract][Full Text] [Related]
10. Fetuin-B links nonalcoholic fatty liver disease to type 2 diabetes via inducing insulin resistance: Association and path analyses.
Li Z; Lin M; Liu C; Wang D; Shi X; Chen Z; Liu Y; Yang S; Li X
Cytokine; 2018 Aug; 108():145-150. PubMed ID: 29609136
[TBL] [Abstract][Full Text] [Related]
11. Osteoprotegerin and osteoprotegerin/TRAIL ratio are associated with cardiovascular dysfunction and mortality among patients with renal failure.
Kuźniewski M; Fedak D; Dumnicka P; Stępień E; Kuśnierz-Cabala B; Cwynar M; Sułowicz W
Adv Med Sci; 2016 Sep; 61(2):269-275. PubMed ID: 27128817
[TBL] [Abstract][Full Text] [Related]
12. Association of plasma osteoprotegerin levels with the severity of lower extremity arterial disease in patients with type 2 diabetes.
Niu Y; Zhang W; Yang Z; Li X; Wen J; Wang S; Zhang H; Wang X; Zhou H; Fang W; Qin L; Su Q
BMC Cardiovasc Disord; 2015 Aug; 15():86. PubMed ID: 26260869
[TBL] [Abstract][Full Text] [Related]
13. Serum osteoprotegerin and tumor necrosis factor related apoptosis inducing-ligand (TRAIL) are elevated in type 2 diabetic patients with albuminuria and serum osteoprotegerin is independently associated with the severity of diabetic nephropathy.
Chang YH; Lin KD; He SR; Hsieh MC; Hsiao JY; Shin SJ
Metabolism; 2011 Aug; 60(8):1064-9. PubMed ID: 21251686
[TBL] [Abstract][Full Text] [Related]
14. Non-alcoholic fatty liver disease predicts type 2 diabetes mellitus, but not prediabetes, in Xi'an, China: a five-year cohort study.
Ming J; Xu S; Gao B; Liu G; Ji Y; Yang F; Jia Y; Fang Y; Ji Q
Liver Int; 2015 Nov; 35(11):2401-7. PubMed ID: 25879672
[TBL] [Abstract][Full Text] [Related]
15. [Correlation analysis of gut microbiota and biochemical indexes in patients with non-alcoholic fatty liver disease].
Ren SM; Mei L; Huang H; Cao SF; Zhao RH; Zheng PY
Zhonghua Gan Zang Bing Za Zhi; 2019 May; 27(5):369-375. PubMed ID: 31177662
[No Abstract] [Full Text] [Related]
16. High Prevalence of Nonalcoholic Fatty Liver Disease in Patients With Type 2 Diabetes Mellitus and Normal Plasma Aminotransferase Levels.
Portillo-Sanchez P; Bril F; Maximos M; Lomonaco R; Biernacki D; Orsak B; Subbarayan S; Webb A; Hecht J; Cusi K
J Clin Endocrinol Metab; 2015 Jun; 100(6):2231-8. PubMed ID: 25885947
[TBL] [Abstract][Full Text] [Related]
17. Osteocalcin and osteoprotegerin levels and their relationship with adipokines and proinflammatory cytokines in children with nonalcoholic fatty liver disease.
El Amrousy D; El-Afify D
Cytokine; 2020 Nov; 135():155215. PubMed ID: 32731119
[TBL] [Abstract][Full Text] [Related]
18. Low serum CTRP3 levels are associated with nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus.
Zhang J; Zhang B; Cheng Y; Xu J
Cytokine; 2018 Jun; 106():131-135. PubMed ID: 29113741
[TBL] [Abstract][Full Text] [Related]
19. Serum osteoprotegerin levels, endothelial function and carotid intima-media thickness in type 2 diabetic patients.
Gunes M; Temizkan S; Apaydin T; Ilgin C; Haklar G; Gogas Yavuz D
J Diabetes Complications; 2021 Dec; 35(12):108073. PubMed ID: 34635402
[TBL] [Abstract][Full Text] [Related]
20. Serum osteoprotegerin and RANKL levels in chronic alcoholic liver disease.
García-Valdecasas-Campelo E; González-Reimers E; Santolaria-Fernández F; De la Vega-Prieto MJ; Milena-Abril A; Sánchez-Pérez MJ; Martínez-Riera A; Gómez-Rodríguez Mde L
Alcohol Alcohol; 2006; 41(3):261-6. PubMed ID: 16476762
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
